Lite Strategy

Lite Strategy EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Lite Strategy (LITS) as of Nov 20, 2026 is -12.27 M USD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -17.46 M USD — a change of -29.71% (higher).

EBITDA

-12.27 MUSD

YoY

-29.71%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Lite Strategy is 2026 -12.27 M USD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Lite Strategy was 2025 -17.46 M USD. It decreases by -29.71% higher compared to the previous year.

The Lite Strategy EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2019
-46.25 M USD
Jan 1, 2020
-25.70 M USD
Jan 1, 2021
-60.42 M USD
Jan 1, 2022
-75.48 M USD
Jan 1, 2023
-36.76 M USD
Jan 1, 2024
14.54 M USD
Jan 1, 2025
-17.46 M USD
Jan 1, 2026
-12.27 M USD
The Lite Strategy EBITDA history
YEAREBITDAYoY
-12.27 MUSD-29.71%
-17.46 MUSD-220.03%
14.54 MUSD-139.55%
-36.76 MUSD-51.30%
-75.48 MUSD+24.92%
-60.42 MUSD+135.11%
-25.70 MUSD-44.43%
-46.25 MUSD+61.77%
-28.59 MUSD-1,301.26%
2.38 MUSD-111.33%
-21.00 MUSD-35.92%
-32.77 MUSD+20.35%
-27.23 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Lite Strategy Stock analysis

What does Lite Strategy do? MEI Pharma, Inc. develops cancer therapies, focusing on clinical drug candidates including Pracinostat, ME-344, and ME-401. Pracinostat, an HDAC inhibitor for hematologic diseases like AML and MDS, has undergone Phase I and II trials. ME-344 targets mitochondrial components in rapidly proliferating cells, while ME-401 inhibits PI3K delta for hematologic cancer treatment. The company generates revenue through clinical development and potential future drug sales, targeting oncology markets with its pipeline of cancer therapies. The firm's products are developed for specific cancer indications, with Pracinostat tested in advanced hematologic malignancies and solid tumors. ME-344 and ME-401 address unmet needs in mitochondrial and PI3K delta pathways, respectively. MEI Pharma's revenue model relies on clinical trial progress and future commercialization of these therapies, aiming to secure partnerships or direct sales in oncology. MEI Pharma's portfolio includes three clinical drug candidates, each targeting distinct cancer mechanisms. Pracinostat is advanced in trials for AML and MDS, while ME-344 and ME-401 are in development for broader cancer applications. The company monetizes through potential drug approvals and sales, with a focus on hematologic cancers and solid tumor markets. Lite Strategy is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Lite Strategy stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Lite Strategy is -12.27 M USD in 2026.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Lite Strategy changed from -17.46 M USD to -12.27 M USD, representing a -29.71% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Lite Strategy since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Lite Strategy historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Lite Strategy

All Key Metrics — Lite Strategy